Combination Treatment Modalities in Cutaneous T-Cell Lymphoma (CTCL)
To access this article, please choose from the options below
This supplement was supported by an unrestricted educational grant from Zeneus Pharma Ltd.
Dr Guitart is a member of the speakers bureau for Ligand Pharmaceutical.
PII: S0093-7754(05)00512-9
doi:10.1053/j.seminoncol.2005.12.018
© 2006 Elsevier Inc. All rights reserved.
